EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial

Khuram Chaudhry, Janaka Karalliedde iD

Diabetes, Obesity and Metabolism · 2024-10 · 26 (S5) · 25-34

DOI: 10.1111/dom.15765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.07.2024. Verfasst von Khuram Chaudhry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) associated with type 2 diabetes (T2DM) is a global challenge; progression to end‐stage kidney disease (ESKD) and increased risk of cardiovascular disease (CVD) associated with advancing nephropathy are a significant source of morbidity, mortality, and healthcare expenditure. Until recently, renin‐angiotensin system (RAS) blockade was the mainstay of pharmacotherapy in diabetic kidney disease (DKD), representing a therapeutic paradigm shift towards interventions that delay disease progression independently of antihypertensive effects. However, a significant residual risk of DKD progression persisted in patients established on RAS blockade, highlighting the need for additional treatment options. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors, originally licensed as glucose‐lowering agents in people with T2DM, serendipitously demonstrated beneficial renal and cardiovascular outcomes in clinical trials designed primarily to evaluate their cardiovascular safety. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was the first to study the effect of SGLT2 inhibition on a primary composite renal endpoint of ESKD, doubling of serum creatinine, or renal or cardiovascular death in 4401 people with T2DM and CKD established on RAS blockade. The trial was stopped early due to efficacy, demonstrating a 30% relative risk reduction in the primary endpoint in the canagliflozin group (hazard ratio 0.70, 95% confidence interval 0.59–0.82; p = 0.00001). Through discussion of the primary analysis from CREDENCE, and selected post hoc analyses, we review the significant benefits highlighted by this landmark study, its role in shaping clinical guidelines, and in re‐establishing interest in interventions that reduce the residual risk of progression of DKD, alongside its interrelation with cardiovascular morbidity and heart failure. We also provide a brief narrative summary of key renal outcome trials since CREDENCE, which indicate emerging avenues for pharmacotherapy beyond SGLT2 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicDisease ProgressionHumansCanagliflozinCardiovascular DiseasesKidney Failure, ChronicHypoglycemic AgentsRandomized Controlled Trials as Topic

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozinHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • School of Cardiovascular, Metabolic Medicine and Sciences, King's College London, London, UK.

ORCID-Profile: Janaka Karalliedde

Zitieren

APA

Chaudhry, K., & Karalliedde, J. (2024). Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial. Diabetes, Obesity and Metabolism, 26(S5), 25-34. https://doi.org/10.1111/dom.15765

Vancouver

Chaudhry K, Karalliedde J. Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial. Diabetes, Obesity and Metabolism. 2024;26(S5):25-34. doi:10.1111/dom.15765

BibTeX
@article{Chaudhry2024,
  author = {Chaudhry, Khuram and Karalliedde, Janaka},
  title = {Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {S5},
  pages = {25--34},
  doi = {10.1111/dom.15765}
}
Kostenlos starten →